PLx Pharma (FRA:1D5A) Retained Earnings : €-181.21 Mil (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. PLx Pharma's retained earnings for the quarter that ended in Sep. 2022 was €-181.21 Mil.

PLx Pharma's quarterly retained earnings declined from Mar. 2022 (€-144.43 Mil) to Jun. 2022 (€-161.69 Mil) and declined from Jun. 2022 (€-161.69 Mil) to Sep. 2022 (€-181.21 Mil).

PLx Pharma's annual retained earnings declined from Dec. 2019 (€-78.24 Mil) to Dec. 2020 (€-83.97 Mil) and declined from Dec. 2020 (€-83.97 Mil) to Dec. 2021 (€-131.22 Mil).

PLx Pharma Retained Earnings Historical Data

The historical data trend for PLx Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Retained Earnings Chart

PLx Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Retained Earnings

Get a 7-Day Free Trial

-56.90

-58.40

-78.24

-83.97

-131.22

PLx Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Retained Earnings	Get a 7-Day Free Trial															-129.06	-131.22	-144.43	-161.69	-181.21

PLx Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

PLx Pharma (FRA:1D5A) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

PLx Pharma (FRA:1D5A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines